# Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

> **NCT07005882** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Azienda Ospedaliero-Universitaria Careggi** · enrollment: 21 (estimated)

## Conditions studied

- Breast Cancer Patients
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HR+/HER2- Breast Cancer
- Radiation Therapy

## Interventions

- **DRUG:** Elacestrant
- **RADIATION:** PULSAR

## Key facts

- **NCT ID:** NCT07005882
- **Lead sponsor:** Azienda Ospedaliero-Universitaria Careggi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07005882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07005882, "Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07005882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*